{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T01:42:22Z","timestamp":1792978942521,"version":"4.5.0"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy Research"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.eplepsyres.2022.107000","type":"journal-article","created":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T09:15:51Z","timestamp":1661246151000},"page":"107000","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Functionalized PEG-PLA nanoparticles for brain targeted delivery of ketoconazole contribute to pregnane X receptor overexpressing in drug-resistant epilepsy"],"prefix":"10.1016","volume":"186","author":[{"given":"Jianhong","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyan","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanbing","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuyang","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"38","key":"10.1016\/j.eplepsyres.2022.107000_bib1","doi-asserted-by":"crossref","first-page":"5142","DOI":"10.1002\/smll.201501167","article-title":"Peptide-like polymers exerting effective glioma-targeted siRNA delivery and release for therapeutic application","volume":"11","author":"An","year":"2015","journal-title":"Small"},{"issue":"32","key":"10.1016\/j.eplepsyres.2022.107000_bib2","doi-asserted-by":"crossref","first-page":"8247","DOI":"10.1200\/JCO.2005.03.1435","article-title":"Management of advanced prostate cancer after first-line chemotherapy","volume":"23","author":"Berthold","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.eplepsyres.2022.107000_bib3","doi-asserted-by":"crossref","first-page":"343","DOI":"10.2165\/00003088-200847050-00005","article-title":"Effect of coadministered ketoconazole, a strong cytochrome P450 3A4 enzyme inhibitor, on the pharmacokinetics of ciclesonide and its active metabolite desisobutyryl-ciclesonide","volume":"47","author":"Bohmer","year":"2008","journal-title":"Clin. Pharmcokinet."},{"issue":"7","key":"10.1016\/j.eplepsyres.2022.107000_bib4","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1124\/dmd.106.014456","article-title":"Valproic acid induces CYP3A4 and MDR1 gene expression by activation of constitutive androstane receptor and pregnane X receptor pathways","volume":"35","author":"Cerveny","year":"2007","journal-title":"Drug Metab. Dispos."},{"issue":"3","key":"10.1016\/j.eplepsyres.2022.107000_bib5","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1001\/jamaneurol.2017.3949","article-title":"Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs: a 30-year Longitudinal Cohort Study","volume":"75","author":"Chen","year":"2018","journal-title":"JAMA Neurol."},{"issue":"4","key":"10.1016\/j.eplepsyres.2022.107000_bib6","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1111\/j.1471-4159.2008.05492.x","article-title":"Involvement of the low-density lipoprotein receptor-related protein in the transcytosis of the brain delivery vector angiopep-2","volume":"106","author":"Demeule","year":"2008","journal-title":"J. Neurochem."},{"issue":"8","key":"10.1016\/j.eplepsyres.2022.107000_bib7","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1634\/theoncologist.12-8-991","article-title":"FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL)","volume":"12","author":"Dinndorf","year":"2007","journal-title":"Oncologist"},{"issue":"12","key":"10.1016\/j.eplepsyres.2022.107000_bib8","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1046\/j.1528-1157.2001.12301.x","article-title":"Overexpression of multiple drug resistance genes in endothelial cells from patients with refractory epilepsy","volume":"42","author":"Dombrowski","year":"2001","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.eplepsyres.2022.107000_bib9","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1124\/mol.107.038398","article-title":"Human pregnane X receptor antagonists and agonists define molecular requirements for different binding sites","volume":"72","author":"Ekins","year":"2007","journal-title":"Mol. Pharmacol."},{"issue":"6","key":"10.1016\/j.eplepsyres.2022.107000_bib10","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s11102-016-0742-1","article-title":"Updates on the role of adrenal steroidogenesis inhibitors in Cushing's syndrome: a focus on novel therapies","volume":"19","author":"Fleseriu","year":"2016","journal-title":"Pituitary"},{"issue":"3","key":"10.1016\/j.eplepsyres.2022.107000_bib11","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s00228-012-1388-1","article-title":"Effect of the CYP3A inhibitor ketoconazole on the PXR-mediated induction of CYP3A activity","volume":"69","author":"Fuchs","year":"2013","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.eplepsyres.2022.107000_bib12","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.nbd.2009.07.028","article-title":"Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases","volume":"37","author":"Gabathuler","year":"2010","journal-title":"Neurobiol. Dis."},{"issue":"6","key":"10.1016\/j.eplepsyres.2022.107000_bib13","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1046\/j.1365-2125.1999.00095.x","article-title":"A cohort study on the risk of acute liver injury among users of ketoconazole and other antifungal drugs","volume":"48","author":"Garcia Rodriguez","year":"1999","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"8","key":"10.1016\/j.eplepsyres.2022.107000_bib14","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1111\/j.1528-1167.2009.02428.x","article-title":"Pattern of P450 expression at the human blood-brain barrier: roles of epileptic condition and laminar flow","volume":"51","author":"Ghosh","year":"2010","journal-title":"Epilepsia"},{"issue":"10","key":"10.1016\/j.eplepsyres.2022.107000_bib15","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1016\/j.drudis.2016.06.004","article-title":"Pathophysiological implications of neurovascular P450 in brain disorders","volume":"21","author":"Ghosh","year":"2016","journal-title":"Drug Discov. Today"},{"issue":"4","key":"10.1016\/j.eplepsyres.2022.107000_bib16","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1111\/epi.13703","article-title":"Overexpression of pregnane X and glucocorticoid receptors and the regulation of cytochrome P450 in human epileptic brain endothelial cells","volume":"58","author":"Ghosh","year":"2017","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.eplepsyres.2022.107000_bib17","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/j.1528-1167.2010.02956.x","article-title":"Cellular localization and functional significance of CYP3A4 in the human epileptic brain","volume":"52","author":"Ghosh","year":"2011","journal-title":"Epilepsia"},{"issue":"8","key":"10.1016\/j.eplepsyres.2022.107000_bib18","doi-asserted-by":"crossref","first-page":"742","DOI":"10.2174\/138920011798357051","article-title":"Blood-brain barrier P450 enzymes and multidrug transporters in drug resistance: a synergistic role in neurological diseases","volume":"12","author":"Ghosh","year":"2011","journal-title":"Curr. Drug Metab."},{"issue":"12","key":"10.1016\/j.eplepsyres.2022.107000_bib19","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1002\/jcph.400","article-title":"Liver injury associated with ketoconazole: review of the published evidence","volume":"54","author":"Greenblatt","year":"2014","journal-title":"J. Clin. Pharmacol."},{"issue":"11","key":"10.1016\/j.eplepsyres.2022.107000_bib20","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/S1474-4422(17)30299-5","article-title":"Global, regional and national burden of neurological disorders during 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015","volume":"16","author":"Group GBDNDC","year":"2017","journal-title":"Lancet Neurol."},{"issue":"2","key":"10.1016\/j.eplepsyres.2022.107000_bib21","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1517\/14740338.2015.983071","article-title":"Drug safety assessment of oral formulations of ketoconazole","volume":"14","author":"Gupta","year":"2015","journal-title":"Expert Opin. Drug Saf."},{"issue":"2","key":"10.1016\/j.eplepsyres.2022.107000_bib22","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/S0022-5347(05)64675-7","article-title":"Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer","volume":"168","author":"Harris","year":"2002","journal-title":"J. Urol."},{"issue":"2","key":"10.1016\/j.eplepsyres.2022.107000_bib23","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/sj.onc.1209788","article-title":"Inhibition of drug metabolism by blocking the activation of nuclear receptors by ketoconazole","volume":"26","author":"Huang","year":"2007","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.eplepsyres.2022.107000_bib24","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1001\/jama.2014.17426","article-title":"Resective epilepsy surgery for drug-resistant focal epilepsy: a review","volume":"313","author":"Jobst","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.eplepsyres.2022.107000_bib25","doi-asserted-by":"crossref","first-page":"6746989","DOI":"10.1155\/2017\/6746989","article-title":"Comparative hepatotoxicity of fluconazole, ketoconazole, itraconazole, terbinafine, and griseofulvin in rats","volume":"2017","author":"Khoza","year":"2017","journal-title":"J. Toxicol."},{"issue":"2","key":"10.1016\/j.eplepsyres.2022.107000_bib26","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s11864-012-0188-2","article-title":"Androgen receptor directed therapies in castration-resistant metastatic prostate cancer","volume":"13","author":"Kim","year":"2012","journal-title":"Curr. Treat. Options Oncol."},{"key":"10.1016\/j.eplepsyres.2022.107000_bib27","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.phrs.2019.04.031","article-title":"ABC transporters in drug-resistant epilepsy: mechanisms of upregulation and therapeutic approaches","volume":"144","author":"Leandro","year":"2019","journal-title":"Pharm. Res."},{"key":"10.1016\/j.eplepsyres.2022.107000_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.brainres.2012.10.060","article-title":"Pregnane X receptor upregulates ABC-transporter Abcg2 and Abcb1 at the blood-brain barrier","volume":"1491","author":"Lemmen","year":"2013","journal-title":"Brain Res."},{"issue":"1","key":"10.1016\/j.eplepsyres.2022.107000_bib29","doi-asserted-by":"crossref","first-page":"242","DOI":"10.3390\/md10010242","article-title":"Fucoxanthin attenuates rifampin-induced cytochrome P450 3A4 (CYP3A4) and multiple drug resistance 1 (MDR1) gene expression through pregnane X receptor (PXR)-mediated pathways in human hepatoma HepG2 and colon adenocarcinoma LS174T cells","volume":"10","author":"Liu","year":"2012","journal-title":"Mar. Drugs"},{"issue":"1","key":"10.1016\/j.eplepsyres.2022.107000_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1081\/DDC-120001481","article-title":"Nanoparticle technology for drug delivery across the blood-brain barrier","volume":"28","author":"Lockman","year":"2002","journal-title":"Drug Dev. Ind. Pharm."},{"issue":"8","key":"10.1016\/j.eplepsyres.2022.107000_bib31","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/nrn1728","article-title":"Drug resistance in brain diseases and the role of drug efflux transporters","volume":"6","author":"Loscher","year":"2005","journal-title":"Nat. Rev. Neurosci."},{"issue":"8","key":"10.1016\/j.eplepsyres.2022.107000_bib32","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1002\/anie.200602866","article-title":"Magnetic nanoparticles: synthesis, protection, functionalization, and application","volume":"46","author":"Lu","year":"2007","journal-title":"Angew. Chem. Int Ed. Engl."},{"issue":"1","key":"10.1016\/j.eplepsyres.2022.107000_bib33","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3109\/03602532.2012.746363","article-title":"PXR antagonists and implication in drug metabolism","volume":"45","author":"Mani","year":"2013","journal-title":"Drug Metab. Rev."},{"issue":"1","key":"10.1016\/j.eplepsyres.2022.107000_bib34","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/clpt.2009.225","article-title":"Transporters in drug-refractory epilepsy: clinical significance","volume":"87","author":"Marchi","year":"2010","journal-title":"Clin. Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.eplepsyres.2022.107000_bib35","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.3892\/ijo.2016.3611","article-title":"Inhibition of pregnane X receptor pathway contributes to the cell growth inhibition and apoptosis of anticancer agents in ovarian cancer cells","volume":"49","author":"Masuyama","year":"2016","journal-title":"Int. J. Oncol."},{"issue":"1","key":"10.1016\/j.eplepsyres.2022.107000_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v12.i1.10","article-title":"Biodegradable microspheres in drug delivery","volume":"12","author":"Okada","year":"1995","journal-title":"Crit. Rev. Ther. Drug Carr. Syst."},{"issue":"3","key":"10.1016\/j.eplepsyres.2022.107000_bib37","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s11481-006-9034-2","article-title":"MDR- and CYP3A4-mediated drug-drug interactions","volume":"1","author":"Pal","year":"2006","journal-title":"J. Neuroimmune Pharmacol."},{"issue":"3","key":"10.1016\/j.eplepsyres.2022.107000_bib38","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/0013-4694(72)90177-0","article-title":"Modification of seizure activity by electrical stimulation. II","volume":"32","author":"Racine","year":"1972","journal-title":"Mot. Seizure Electron. Clin. Neurophysiol."},{"issue":"Pt 1","key":"10.1016\/j.eplepsyres.2022.107000_bib39","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1093\/brain\/awh682","article-title":"Molecular and cellular mechanisms of pharmacoresistance in epilepsy","volume":"129","author":"Remy","year":"2006","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.eplepsyres.2022.107000_bib40","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0306-4522(02)00064-7","article-title":"Evolution of hippocampal epileptic activity during the development of hippocampal sclerosis in a mouse model of temporal lobe epilepsy","volume":"112","author":"Riban","year":"2002","journal-title":"Neuroscience"},{"key":"10.1016\/j.eplepsyres.2022.107000_bib41","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.toxlet.2020.07.012","article-title":"Dechlorination and demethylation of ochratoxin A enhance blocking activity of PXR activation, suppress PXR expression and reduce cytotoxicity","volume":"332","author":"Shen","year":"2020","journal-title":"Toxicol. Lett."},{"issue":"1","key":"10.1016\/j.eplepsyres.2022.107000_bib42","first-page":"17","article-title":"Drug-resistant epilepsy and surgery","volume":"16","author":"Sheng","year":"2018","journal-title":"Curr. Neuropharmacol."},{"issue":"4","key":"10.1016\/j.eplepsyres.2022.107000_bib43","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/j.1875-9114.1984.tb03356.x","article-title":"Ketoconazole: an orally effective antifungal agent. Mechanism of action, pharmacology, clinical efficacy and adverse effects","volume":"4","author":"Smith","year":"1984","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.eplepsyres.2022.107000_bib44","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.jconrel.2013.11.023","article-title":"Insight on the fate of CNS-targeted nanoparticles. Part I: Rab5-dependent cell-specific uptake and distribution","volume":"174","author":"Vilella","year":"2014","journal-title":"J. Control. Release"},{"issue":"3","key":"10.1016\/j.eplepsyres.2022.107000_bib45","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/s41551-020-00618-4","article-title":"An electric-field-responsive paramagnetic contrast agent enhances the visualization of epileptic foci in mouse models of drug-resistant epilepsy","volume":"5","author":"Wang","year":"2021","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.eplepsyres.2022.107000_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.103156","article-title":"Imaging epileptic foci in mouse models via a low-density lipoprotein receptor-related protein-1 targeting strategy","volume":"63","author":"Wang","year":"2021","journal-title":"EBioMedicine"},{"issue":"8","key":"10.1016\/j.eplepsyres.2022.107000_bib47","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1158\/1078-0432.CCR-06-1592","article-title":"Activated pregnenolone X-receptor is a target for ketoconazole and its analogs","volume":"13","author":"Wang","year":"2007","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.eplepsyres.2022.107000_bib48","doi-asserted-by":"crossref","first-page":"12143","DOI":"10.1021\/acsami.0c00509","article-title":"Angiopep2-conjugated star-shaped polyprodrug amphiphiles for simultaneous glioma-targeting therapy and MR imaging","volume":"12","author":"Wang","year":"2020","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"12","key":"10.1016\/j.eplepsyres.2022.107000_bib49","doi-asserted-by":"crossref","first-page":"8392","DOI":"10.1007\/s12035-019-01673-y","article-title":"Neurovascular drug biotransformation machinery in focal human epilepsies: brain CYP3A4 correlates with seizure frequency and antiepileptic drug therapy","volume":"56","author":"Williams","year":"2019","journal-title":"Mol. Neurobiol."},{"issue":"50","key":"10.1016\/j.eplepsyres.2022.107000_bib50","doi-asserted-by":"crossref","DOI":"10.1088\/1361-6528\/ab4241","article-title":"Magnetic nanoparticles in nanomedicine: a review of recent advances","volume":"30","author":"Wu","year":"2019","journal-title":"Nanotechnology"},{"issue":"3","key":"10.1016\/j.eplepsyres.2022.107000_bib51","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.neulet.2008.01.071","article-title":"Increased P-glycoprotein function and level after long-term exposure of four antiepileptic drugs to rat brain microvascular endothelial cells in vitro","volume":"434","author":"Yang","year":"2008","journal-title":"Neurosci. Lett."},{"issue":"1","key":"10.1016\/j.eplepsyres.2022.107000_bib52","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1124\/jpet.102.037549","article-title":"Interaction of cytochrome P450 3A inhibitors with P-glycoprotein","volume":"303","author":"Yasuda","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"9","key":"10.1016\/j.eplepsyres.2022.107000_bib53","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.7150\/thno.23789","article-title":"Surface impact on nanoparticle-based magnetic resonance imaging contrast agents","volume":"8","author":"Zhang","year":"2018","journal-title":"Theranostics"}],"container-title":["Epilepsy Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121122001516?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121122001516?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:48:03Z","timestamp":1760276883000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920121122001516"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":53,"alternative-id":["S0920121122001516"],"URL":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2022.107000","relation":{},"ISSN":["0920-1211"],"issn-type":[{"value":"0920-1211","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Functionalized PEG-PLA nanoparticles for brain targeted delivery of ketoconazole contribute to pregnane X receptor overexpressing in drug-resistant epilepsy","name":"articletitle","label":"Article Title"},{"value":"Epilepsy Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2022.107000","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107000"}}